{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:54:33Z","timestamp":1785372873595,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40264-025-01561-6","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T13:46:55Z","timestamp":1749563215000},"page":"1127-1139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of Adverse Events in Pregnant Persons Receiving COVID-19 and Influenza Vaccines: A Disproportionality Analysis Using Combined Data from US VAERS and EudraVigilance Spontaneous Report Databases"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5878-5088","authenticated-orcid":false,"given":"Leonardo","family":"Roque-Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malede Mequanent","family":"Sisay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Comfort K.","family":"Ogar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1853-3641","authenticated-orcid":false,"given":"Carlos E.","family":"Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"van Puijenbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Verhamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Sturkenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"1561_CR1","unstructured":"Ahmed I, Poncet A. PhViD: An R package for pharmacovigilance signal detection; 2016. Accessed 25 June 2024. https:\/\/www.researchgate.net\/publication\/303894843"},{"key":"1561_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000182483.24836.66","author":"WH Goodnight","year":"2005","unstructured":"Goodnight WH, Soper DE. Pneumonia in pregnancy. Crit Care Med. 2005. https:\/\/doi.org\/10.1097\/01.CCM.0000182483.24836.66.","journal-title":"Crit Care Med"},{"key":"1561_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2022.03.060","author":"H Wang","year":"2022","unstructured":"Wang H, Li N, Sun C, et al. The association between pregnancy and COVID-19: a systematic review and meta-analysis. Am J Emerg Med. 2022. https:\/\/doi.org\/10.1016\/j.ajem.2022.03.060.","journal-title":"Am J Emerg Med"},{"key":"1561_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccc.2022.01.003","author":"M Levitus","year":"2022","unstructured":"Levitus M, Shainker SA, Colvin M. COVID-19 in the critically ill pregnant patient. Crit Care Clin. 2022. https:\/\/doi.org\/10.1016\/j.ccc.2022.01.003.","journal-title":"Crit Care Clin"},{"key":"1561_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.wombi.2020.10.015","author":"P Pavlidis","year":"2021","unstructured":"Pavlidis P, Eddy K, Phung L, et al. Clinical guidelines for caring for women with COVID-19 during pregnancy, childbirth and the immediate postpartum period. Women Birth. 2021. https:\/\/doi.org\/10.1016\/j.wombi.2020.10.015.","journal-title":"Women Birth."},{"key":"1561_CR6","unstructured":"Centre for Disease Control and Prevention. People with certain medical conditions. Morbility and Mortality Weekly Reports. Accessed 2 Feb 2024 in https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-with-medical-conditions.html."},{"key":"1561_CR7","unstructured":"World Health Organization. Questions and answers: COVID-19 vaccines and pregnancy. Accessed 25 Mar 2024 in: https:\/\/iris.who.int\/bitstream\/handle\/10665\/351855\/WHO-2019-nCoV-FAQ-Pregnancy-Vaccines-2022.1-eng.pdf?sequence=1."},{"key":"1561_CR8","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1712103","author":"DD Smith","year":"2020","unstructured":"Smith DD, Pippen JL, Adesomo AA, Rood KM, Landon MB, Costantine MM. Exclusion of pregnant women from clinical trials during the coronavirus disease 2019 pandemic: a review of international registries. Am J Perinatol. 2020. https:\/\/doi.org\/10.1055\/s-0040-1712103.","journal-title":"Am J Perinatol"},{"key":"1561_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.035","author":"TT Shimabukuro","year":"2015","unstructured":"Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the vaccine adverse event reporting system (VAERS). Vaccine. 2015. https:\/\/doi.org\/10.1016\/j.vaccine.2015.07.035.","journal-title":"Vaccine"},{"key":"1561_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0647-1","author":"R Postigo","year":"2018","unstructured":"Postigo R, Brosch S, Slattery J, et al. EudraVigilance medicines safety database: publicly accessible data for research and public health protection. Drug Saf. 2018. https:\/\/doi.org\/10.1007\/s40264-018-0647-1.","journal-title":"Drug Saf"},{"key":"1561_CR11","unstructured":"CIOMS. CIOMS VIII - Practical aspects of signal detection in pharmacovigilance. ; 2010; Vol 41"},{"key":"1561_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/S1875-5364(13)60035-7","author":"RC Zink","year":"2013","unstructured":"Zink RC, Huang Q, Zhang LY, Bao WJ. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance. Chin J Nat Med. 2013. https:\/\/doi.org\/10.1016\/S1875-5364(13)60035-7.","journal-title":"Chin J Nat Med"},{"key":"1561_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2019.01.006","author":"JL Faillie","year":"2019","unstructured":"Faillie JL. Case\u2013non-case studies: principle, methods, bias and interpretation. Therapie. 2019. https:\/\/doi.org\/10.1016\/j.therap.2019.01.006.","journal-title":"Therapie"},{"key":"1561_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.04.031","author":"PL Moro","year":"2022","unstructured":"Moro PL, Olson CK, Clark E, et al. Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 \u2013 October 2021. Vaccine. 2022. https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.031.","journal-title":"Vaccine"},{"key":"1561_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.965171","author":"A Mascolo","year":"2022","unstructured":"Mascolo A, di Mauro G, Fraenza F, et al. Maternal, fetal and neonatal outcomes among pregnant women receiving COVID-19 vaccination: the preg-co-vax study. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.965171.","journal-title":"Front Immunol"},{"key":"1561_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.921760","author":"MM Yan","year":"2022","unstructured":"Yan MM, Zhao H, Li ZR, et al. Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: gaining insight through the VAERS. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.921760.","journal-title":"Front Pharmacol"},{"key":"1561_CR17","unstructured":"European Medicine Agency. The withdrawn applications and products. Accessed 2 October 2024 in: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/public-health-threats\/coronavirus-disease-covid-19\/covid-19-public-health-emergency-international-concern-2020-23\/withdrawn-applications-products."},{"key":"1561_CR18","doi-asserted-by":"publisher","unstructured":"Zaccaria C, Piccolo L, Gordillo-Mara\u00f1\u00f3n M, Touraille G, de Vries C. Identification of pregnancy adverse drug reactions in pharmacovigilance reporting systems: a novel algorithm developed in EudraVigilance. Drug Saf. Published online 1 November 2024. https:\/\/doi.org\/10.1007\/s40264-024-01448-y","DOI":"10.1007\/s40264-024-01448-y"},{"key":"1561_CR19","unstructured":"Dodd NC. Using existing data sources for assessment of vaccine safety a focus on methods. [PhD Diss]. Erasmus University; 2019. Accessed 5 Dec 2024. https:\/\/repub.eur.nl\/pub\/117427\/Dodd_Corrected_27MAY2019_2.pdf"},{"issue":"6","key":"1561_CR20","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, et al. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): explanation and elaboration. Drug Saf. 2024;47(6):585\u201399. https:\/\/doi.org\/10.1007\/s40264-024-01423-7.","journal-title":"Drug Saf"},{"key":"1561_CR21","doi-asserted-by":"crossref","unstructured":"Frcp CBEDSC. Austin Bradford Hill, \u201cThe environment and disease: association or causation?, \u201d Society. 1965;58.","DOI":"10.1177\/003591576505800503"},{"key":"1561_CR22","unstructured":"Digital Research Environment (DRE). Accessed 30 Jan 2024 in: https:\/\/mydre.org."},{"key":"1561_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2010.08.050","author":"PL Moro","year":"2011","unstructured":"Moro PL, Broder K, Zheteyeva Y, et al. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the vaccine adverse event reporting system, 1990\u20132009. Am J Obstet Gynecol. 2011. https:\/\/doi.org\/10.1016\/j.ajog.2010.08.050.","journal-title":"Am J Obstet Gynecol"},{"key":"1561_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2009.09.034","author":"PD Tamma","year":"2009","unstructured":"Tamma PD, Ault KA, del Rio C, Steinhoff MC, Halsey NA, Omer SB. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol. 2009. https:\/\/doi.org\/10.1016\/j.ajog.2009.09.034.","journal-title":"Am J Obstet Gynecol"},{"key":"1561_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-066182","author":"DM Wolfe","year":"2023","unstructured":"Wolfe DM, Fell D, Garritty C, et al. Safety of influenza vaccination during pregnancy: a systematic review. BMJ Open. 2023. https:\/\/doi.org\/10.1136\/bmjopen-2022-066182.","journal-title":"BMJ Open"},{"key":"1561_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.04.021","author":"AL Naleway","year":"2014","unstructured":"Naleway AL, Irving SA, Henninger ML, et al. Safety of influenza vaccination during pregnancy: a review of subsequent maternal obstetric events and findings from two recent cohort studies. Vaccine. 2014. https:\/\/doi.org\/10.1016\/j.vaccine.2014.04.021.","journal-title":"Vaccine"},{"key":"1561_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2005.07.091","author":"V Pool","year":"2006","unstructured":"Pool V, Iskander J. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol. 2006. https:\/\/doi.org\/10.1016\/j.ajog.2005.07.091.","journal-title":"Am J Obstet Gynecol"},{"key":"1561_CR28","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2024.39.e3","author":"D Kang","year":"2024","unstructured":"Kang D, Choi A, Park S, Choe SA, Shin JY. Safety of COVID-19 vaccination during pregnancy and lactation: a VigiBase analysis. J Korean Med Sci. 2024. https:\/\/doi.org\/10.3346\/jkms.2024.39.e3.","journal-title":"J Korean Med Sci"},{"key":"1561_CR29","unstructured":"European Parliament and Council. Regulation (EC) No 726\/2004 of the European Parliament and of the Council. OJEU. 2004;L269."},{"key":"1561_CR30","unstructured":"CD. DIRECTIVE 2001\/83\/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 November 2001 on the Community code relating to medicinal products for human use. Official Journal of the European Communities. 2001;1(28 September 2001)."},{"key":"1561_CR31","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Clinical safety data management: definitions and standards for expedited reporting E2A current step 4 version. 1994. Accessed 8 Dec 2024. https:\/\/www.ema.europa.eu\/en\/ich-e2a-clinical-safety-data-management-definitions-standards-expedited-reporting-scientific-guideline\u200b"},{"key":"1561_CR32","unstructured":"Module on safety surveillance of COVID-19 vaccines in pregnant and breastfeeding women. Geneva, Switzerland: World health organization. 2021. Accessed 15 Dec 2024. https:\/\/iris.who.int\/bitstream\/handle\/10665\/342538\/WHO-MHP-RPQ-PVG-2021.1-eng.pdf"},{"key":"1561_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00913-0","author":"I Casubhoy","year":"2024","unstructured":"Casubhoy I, Kretz A, Tan HL, et al. A scoping review of global COVID-19 vaccine hesitancy among pregnant persons. NPJ Vaccines. 2024. https:\/\/doi.org\/10.1038\/s41541-024-00913-0.","journal-title":"NPJ Vaccines"},{"issue":"16","key":"1561_CR34","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.vaccine.2019.03.003","volume":"37","author":"BL Hoffman","year":"2019","unstructured":"Hoffman BL, Felter EM, Chu KH, et al. It\u2019s not all about autism: the emerging landscape of anti-vaccination sentiment on Facebook. Vaccine. 2019;37(16):2216\u201323. https:\/\/doi.org\/10.1016\/j.vaccine.2019.03.003.","journal-title":"Vaccine"},{"key":"1561_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.15494","author":"EO Kharbanda","year":"2021","unstructured":"Kharbanda EO, Haapala J, Desilva M, et al. Spontaneous abortion following COVID-19 vaccination during pregnancy. JAMA. 2021. https:\/\/doi.org\/10.1001\/jama.2021.15494.","journal-title":"JAMA"},{"issue":"9","key":"1561_CR36","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1210\/jc.2008-2521","volume":"94","author":"FC Soardi","year":"2009","unstructured":"Soardi FC, Penachioni JY, Justo GZ, et al. Novel mutations in CYP11B1 gene leading to 11\u03b2-Hydroxylase deficiency in Brazilian patients. J Clin Endocrinol Metab. 2009;94(9):3481\u20135. https:\/\/doi.org\/10.1210\/jc.2008-2521.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1561_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1210\/jc.2003-031021","volume":"89","author":"M Costa-Santos","year":"2004","unstructured":"Costa-Santos M, Kater CE, Auchus RJ. Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-Hydroxylase deficiency. J Clin Endocrinol Metab. 2004;89(1):49\u201360. https:\/\/doi.org\/10.1210\/jc.2003-031021.","journal-title":"J Clin Endocrinol Metab"},{"key":"1561_CR38","unstructured":"Medicines Agency E. EudraVigilance user manual - Individual case safety report form. 2018. www.ema.europa.eu\/contact"},{"key":"1561_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjae.2020.10.003","author":"R Kearsley","year":"2021","unstructured":"Kearsley R, Stocks G. Venous thromboembolism in pregnancy\u2014diagnosis, management, and treatment. BJA Educ. 2021. https:\/\/doi.org\/10.1016\/j.bjae.2020.10.003.","journal-title":"BJA Educ."},{"key":"1561_CR40","unstructured":"Rebordosa C. A Post-authorisation\/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources (COVID-19). 2024. Accessed 24 April 2025. https:\/\/catalogues.ema.europa.eu\/node\/3319\/administrative-details"},{"key":"1561_CR41","unstructured":"Lusignan S. An assessment of a relationship between the exposure to COVID-19 vaccines and risk of thrombotic thrombocytopenia syndrome (Association of the Risk for Thrombotic Thrombocytopenia Syndrome and Exposure To COVID-19 Vaccines) - ATTEST Study. 2024. Accessed 25 April 2025. https:\/\/catalogues.ema.europa.eu\/node\/3392\/administrative-details"},{"key":"1561_CR42","unstructured":"Ahmadizar F. An observational post-authorisation safety study to assess the safety of Ad26.COV2.S using European healthcare data through VAC4EU.; 2025. Accessed 25 April 2025. https:\/\/catalogues.ema.europa.eu\/node\/3338\/administrative-details"},{"key":"1561_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00569-8","author":"A Buoninfante","year":"2022","unstructured":"Buoninfante A, Andeweg A, Baker AT, et al. Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination. NPJ Vaccines. 2022. https:\/\/doi.org\/10.1038\/s41541-022-00569-8.","journal-title":"NPJ Vaccines."},{"key":"1561_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117607","author":"M Sharifian-Dorche","year":"2021","unstructured":"Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, Mowla A. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. J Neurol Sci. 2021. https:\/\/doi.org\/10.1016\/j.jns.2021.117607.","journal-title":"J Neurol Sci"},{"key":"1561_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac080","author":"L Pischel","year":"2022","unstructured":"Pischel L, Patel KM, Goshua G, Omer SB. Adenovirus-based vaccines and thrombosis in pregnancy: a systematic review and meta-analysis. Clin Infect Dis. 2022. https:\/\/doi.org\/10.1093\/cid\/ciac080.","journal-title":"Clin Infect Dis"},{"key":"1561_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101037","author":"E Raffetti","year":"2024","unstructured":"Raffetti E, Bolton T, Nolan J, et al. COVID-19 diagnosis, vaccination during pregnancy, and adverse pregnancy outcomes of 865,654 women in England and Wales: a population-based cohort study. Lancet Reg Health Eur. 2024. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101037.","journal-title":"Lancet Reg Health Eur"},{"key":"1561_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/pds.677","author":"SJW Evans","year":"2001","unstructured":"Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001. https:\/\/doi.org\/10.1002\/pds.677.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1561_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0075-1","author":"J Slattery","year":"2013","unstructured":"Slattery J, Alvarez Y, Hidalgo A. Choosing thresholds for statistical signal detection with the proportional reporting ratio. Drug Saf. 2013. https:\/\/doi.org\/10.1007\/s40264-013-0075-1.","journal-title":"Drug Saf"},{"key":"1561_CR49","unstructured":"Department of Health U, Services H. VAERS data use guide contents. https:\/\/www.meddra.org\/."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01561-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01561-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01561-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T13:52:08Z","timestamp":1757512328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01561-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1561"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01561-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"8 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript has not been funded by any party. This study has been developed in the context of the PhD research trajectory of the first study author (L.R.P.).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Leonardo Roque-Pereira is an employee of Roche\/Genentech. Nonetheless, this paper only reflects the personal views of the stated authors. Eugene Van Puijenbroek is an Editorial Board Member of the journal Drug Safety. Eugene Van Puijenbroek was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. The other authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"No ethics approval was required for this study as it includes essentially only public data transformation. It should be noted that the original data are either publicly available, or data are anonymized and cannot be linked to a patient. An independent quality check has been carried out by Utrecht Medical Centre University to ensure compliance with legislation and regulations (regarding informed consent procedure, data management, privacy aspects and legal aspects). This study does not fall under the scope of the Dutch Medical Research Involving Human Subjects Act (WMO) and therefore does not require approval from an accredited MREC in the Netherlands.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This study includes only anonymized and publicly available patient-related data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The raw dataset from VAERS is available in the public domain. The raw data from EudraVigilance were provided by the European Medicines Agency (EMA) after a formal request. Therefore, the authors made some data available in the supplementary materials, omitting the report ID. The Electronic Supplementary Materials\/Online Resources can be accessed in the following data repository: Roque-Pereira, L. (2025). Online Resources\/Supplementary Materials for the article: Comparison of adverse events in pregnant persons receiving COVID-19 and influenza vaccines: a disproportionality analysis using combined data from US VAERS and EudraVigilance spontaneous report databases. Zenodo. .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"MedDRA Dictionary version 27.0 was used for the classification of Preferred Terms into the High-Level Group Terms. All data processing and statistical analysis were performed using R version 4.3.1, with the package \u2018PhViD\u2019 and OpenEBGM []. A virtual folder titled Digital Research Environment (DRE) was created on 30 January 2024.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization of the study\u2014Leonardo Roque-Pereira, Malede Mequanent Sisay, Comfort K. Ogar, Carlos E. Dur\u00e1n, Daniel Weibel, Eugene Van Puijenbroek, Katia Verhamme, and Miriam Sturkenboom; dataset request\/acquisition and handling\u2014Leonardo Roque-Pereira and Malede Mequanent Sisay; codes\/script creation in R\u2014Malede Mequanent Sisay; data interpretation and data analysis\u2014Leonardo Roque-Pereira, Malede Mequanent Sisay, Comfort K. Ogar, Carlos E. Dur\u00e1n, Daniel Weibel, Eugene Van Puijenbroek, Katia Verhamme, and Miriam Sturkenboom; draft of the manuscript\u2014Leonardo Roque-Pereira; review and comments on the manuscript\u2014all authors; all authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}